Effect of anti-TNF treatment on body composition and serum adiponectin levels of women with rheumatoid arthritis.
The aim of this study was to investigate the effect of anti-tumor necrosis factor alpha (anti-TNF) treatment on body composition and serum adiponectin levels of women with rheumatoid arthritis (RA). Nineteen women with RA starting anti-TNF treatment were included in the study. Disease activity, body composition, lumbar spine bone mineral density (BMD) and serum adiponectin concentrations were measured at baseline and after 1 year of follow-up. No important changes on body composition and lumbar spine BMD were observed, while the serum levels of adiponectin levels increased after 1 year of anti-TNF treatment (p = 0.02). Anti-TNF treatment in women with RA does not have any significant effect on body composition; however, it is associated with increase in adiponectin levels which may ameliorate the systemic inflammatory response state associated with RA.
Serelis
John
J
Department of Internal Medicine, Athens Euroclinic, 7 Athanasiadou Str, Athens 11521, Greece.
Kontogianni
Meropi D
MD
Katsiougiannis
Stergios
S
Bletsa
Maria
M
Tektonidou
Maria G
MG
Skopouli
Fotini N
FN
D052242:Adiponectin / Q000097:blood; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D018501:Antirheumatic Agents / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D001823:Body Composition / Q000187:drug effects*; D015519:Bone Density / Q000187:drug effects; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D013256:Steroids / Q000008:administration & dosage; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
C499918:ADIPOQ protein, human; D052242:Adiponectin; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D013256:Steroids; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D008727:Methotrexate